Pyrazole-amide compounds and pharmaceutical use thereof

Abstract

A compound represented by the following formula: wherein n is 1 or 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutical use thereof.

1 .- 11 . (canceled) 
     
     
         12 . A method for the prophylaxis of diabetes, insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications, cardiac failure, cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer or pulmonary hypertension in a mammal, comprising administering a pharmaceutically effective amount of a compound selected from the group consisting of:
 i) a compound represented by formula [I]:   
       
         
           
           
               
               
           
         
          wherein n is 1 or 2, 
         ii) a compound represented by formula [II]: 
       
       
         
           
           
               
               
           
         
         iii) a compound represented by formula [IIh]: 
       
       
         
           
           
               
               
           
         
          and 
         iv) a compound represented by formula [III]: 
       
       
         
           
           
               
               
           
         
          and 
       
       pharmaceutically acceptable salts thereof, to the mammal. 
     
     
         13 . The method according to  claim 12 , wherein the diabetes is type 1 diabetes or type 2 diabetes. 
     
     
         14 . The method according to  claim 12 , wherein the diabetic complications are selected from the group consisting of diabetic neuropathy, diabetic retinopathy, diabetic nephropathy and cataract. 
     
     
         15 . The method according to  claim 12 , wherein the cardiac failure is acute cardiac failure or chronic cardiac failure. 
     
     
         16 . The method according to  claim 13 , wherein the diabetes is type 2 diabetes. 
     
     
         17 . The method according to  claim 12 , wherein the compound is represented by formula [I]. 
     
     
         18 . The method according to  claim 12 , wherein the compound is represented by formula [II]. 
     
     
         19 . The method according to  claim 12 , wherein the compound is represented by formula [IIh]. 
     
     
         20 . The method according to  claim 12 , wherein the compound is represented by formula [III].